{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:11:12Z","timestamp":1787911872806,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,17]]},"DOI":"10.7759\/cureus.75907","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:24:01Z","timestamp":1734499441000},"source":"Crossref","is-referenced-by-count":4,"title":["Aducanumab in Alzheimer\u2019s Disease: A Comparative Study of Its Effects on Dementia and Mild Cognitive Impairment"],"prefix":"10.7759","author":[{"given":"Andrea","family":"Medel S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Ortiz Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro A","family":"Moreno Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Salas L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz E","family":"Madrigal G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K","family":"Dominguez Ibarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz A","family":"Guti\u00e9rrez Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar O","family":"Garcia Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo T","family":"Moreno Becerril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Montelongo Quevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R","family":"Flores Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"What is Alzheimer\u2019s disease? Symptoms &amp; causes. (2024). https.\/\/www.alz.org\/alzheimers-dementia\/what-is-alzheimers?lang=en-US."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2021.102914","article-title":"Plasma neurofilament L to amyloid \u03b242 ratio in differentiating Alzheimer\u2019s type from non-Alzheimer\u2019s dementia: a cross-sectional pilot study from India","volume":"66","author":"Subramanian S","year":"2021","unstructured":"Subramanian S, Krishna G, Sivakumar PT, Dahale AB, Kumar J S, Sinha P, Varghese M. Plasma neurofilament L to amyloid \u03b242 ratio in differentiating Alzheimer\u2019s type from non-Alzheimer\u2019s dementia: a cross-sectional pilot study from India. Asian J Psychiatr. 2021, 66:102914. 10.1016\/j.ajp.2021.102914","journal-title":"Asian J Psychiatr"},{"key":"ref3","unstructured":"FDA grants accelerated approval for Alzheimer\u2019s drug. Accessed. March 24, 2024: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.33588\/rn.6611.2017519","article-title":"Epidemiology of alzheimer\u2019s disease and other dementias","volume":"66","author":"Garre-Olmo J","year":"2018","unstructured":"Garre-Olmo J. Epidemiology of alzheimer\u2019s disease and other dementias. Rev Neurol. 2018, 66:377-86. 10.33588\/rn.6611.2017519","journal-title":"Rev Neurol"},{"key":"ref5","unstructured":"Dementia. number of people affected to triple in next 30 years. (2017). https:\/\/www.who.int\/news\/item\/07-12-2017-dementia-number-of-people-affected-to-triple-in-next-30-years."},{"key":"ref6","unstructured":"\u00bfC\u00f3mo se trata la enfermedad de Alzheimer? | National Institute on Aging. Accessed. March 24, 2024: https:\/\/www.nia.nih.gov\/espanol\/cuidado-medico-enfermedad-alzheimer\/como-se-trata-enfermedad-alzheimer."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings J","year":"2021","unstructured":"Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021, 8:398-410. 10.14283\/jpad.2021.41","journal-title":"J Prev Alzheimers Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2","volume":"8","author":"Arndt JW","year":"2018","unstructured":"Arndt JW, Qian F, Smith BA, et al.. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2. Sci Rep. 2018, 8:6412. 10.1038\/s41598-018-24501-0","journal-title":"Sci Rep"},{"key":"ref9","unstructured":"Aduhelm | European Medicines Agency. (2024). https.\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aduhelm."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004710","article-title":"FDG PET (and MRI) for monitoring immunotherapy in Alzheimer disease","volume":"48","author":"H\u00f8ilund-Carlsen PF","year":"2023","unstructured":"H\u00f8ilund-Carlsen PF, Revheim ME, Alavi A, Barrio JR. FDG PET (and MRI) for monitoring immunotherapy in Alzheimer disease. Clin Nucl Med. 2023, 48:689-91. 10.1097\/RLU.0000000000004710","journal-title":"Clin Nucl Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway S","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, et al.. Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022, 79:13-21. 10.1001\/jamaneurol.2021.4161","journal-title":"JAMA Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51422","article-title":"10 steps to conduct a systematic review","volume":"15","author":"Calderon Martinez E","year":"2023","unstructured":"Calderon Martinez E, Flores Vald\u00e9s JR, Castillo JL, et al.. 10 steps to conduct a systematic review. Cureus. 2023, 15:e51422. 10.7759\/cureus.51422","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized Phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein S","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, et al.. Two randomized Phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022, 9:197-210. 10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.6","article-title":"Investigating partially discordant results in phase 3 studies of aducanumab","volume":"10","author":"Mallinckrodt C","year":"2023","unstructured":"Mallinckrodt C, Tian Y, Aisen PS, et al.. Investigating partially discordant results in phase 3 studies of aducanumab. J Prev Alzheimers Dis. 2023, 10:171-7. 10.14283\/jpad.2023.6","journal-title":"J Prev Alzheimers Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13431","article-title":"Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease","volume":"20","author":"Pang M","year":"2024","unstructured":"Pang M, Gabelle A, Saha-Chaudhuri P, et al.. Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease. Alzheimers Dement. 2024, 20:1102-11. 10.1002\/alz.13431","journal-title":"Alzheimers Dement"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13755","article-title":"Results from the long-term extension of PRIME: a randomized Phase 1b trial of aducanumab","volume":"20","author":"Chen T","year":"2024","unstructured":"Chen T, O'Gorman J, Castrillo-Viguera C, et al.. Results from the long-term extension of PRIME: a randomized Phase 1b trial of aducanumab. Alzheimers Dement. 2024, 20:3406-15. 10.1002\/alz.13755","journal-title":"Alzheimers Dement"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny J","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, et al.. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease. Nature. 2016, 537:50-6. 10.1038\/nature19323","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.48","article-title":"The future of ad clinical trials with the advent of anti-amyloid therapies: an CTAD task force report","volume":"9","author":"Delrieu J","year":"2022","unstructured":"Delrieu J, Bateman RJ, Touchon J, Sabbagh M, Cummings J. The future of ad clinical trials with the advent of anti-amyloid therapies: an CTAD task force report. J Prev Alzheimers Dis. 2022, 9:393-9. 10.14283\/jpad.2022.48","journal-title":"J Prev Alzheimers Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01512-w","article-title":"The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wu W","year":"2023","unstructured":"Wu W, Ji Y, Wang Z, et al.. The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res. 2023, 28:544. 10.1186\/s40001-023-01512-w","journal-title":"Eur J Med Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/311942-aducanumab-in-alzheimers-disease-a-comparative-study-of-its-effects-on-dementia-and-mild-cognitive-impairment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:24:06Z","timestamp":1734499446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/311942-aducanumab-in-alzheimers-disease-a-comparative-study-of-its-effects-on-dementia-and-mild-cognitive-impairment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.75907","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}